Decipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/in Retrospective studies/by MaxStatins Linked to Improved Survival in Advanced Prostate Cancer Patients on Apalutamide
/in Post-hoc, Retrospective studies/by MaxNutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology
/in Retrospective studies/by MaxFracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/in Retrospective studies/by MaxReal-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxRetrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/in Retrospective studies/by MaxReal-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/in Retrospective studies/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/in Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
- Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors April 20, 2026